Name: Lupeol
Brand: Selleck Chemicals
SKU: S3614
Rating: 5 (2 reviews)

Lupeol (Clerodol, Monogynol B, Fagarasterol, Farganasterol) is a significant lupane-type triterpene represented in the plant, fungi and animal kingdoms with anticancer, antiprotozoal, chemopreventive and anti-inflammatory properties.

Lupeol Chemical Structure

CAS: 545-47-1

Selleck's Lupeol has been cited by 2 publications

Purity & Quality Control

Batch: Purity: 100.00%

100.00

Lupeol Related Products

Choose Selective Immunology & Inflammation related Inhibitors

Biological Activity

Description	Lupeol (Clerodol, Monogynol B, Fagarasterol, Farganasterol) is a significant lupane-type triterpene represented in the plant, fungi and animal kingdoms with anticancer, antiprotozoal, chemopreventive and anti-inflammatory properties.

In vitro
In vitro	Lupeol is a multi-target agent with immense anti-inflammatory potential targeting key molecular pathways which involve nuclear factor kappa B (NFκB), cFLIP, Fas, Kras, phosphatidylinositol-3-kinase (PI3K)/Akt and Wnt/β-catenin in a variety of cells. Lupeol can induce apoptosis of human promyelotic HL-60 leukemia cells and induce the formation of hypodiploid nuclei and fragmentation of DNA in a dose and time dependent manner. Lupeol induces death of cancer cell lines of various histopathological origins, including T-lymphoblastic leukemia CEM (IC50 = 50 μM), breast carcinoma MCF-7 (IC50 = 50 μM), lung carcinoma A-549 (IC50 = 50 μM), multiple myeloma RPMI 8226 (IC50 = 50 μM), cervical carcinoma HeLa (IC50 = 37 μM), and malignant melanoma G361 (IC50 = 50 μM) when treated for 72 h. Lupeol also inhibits the proliferation of the ERα-negative breast cancer cells MDA-MB-231. Lupeol (50-30 μg/ml) exhibits anti-angiogenic property in an in vitro tube formation model of human umbilical venous endothelial cells. It inhibits the PI3K/Akt, NFκB signaling network, and decreases the activity of Ras protein (GTP-bound Ras) in pancreatic cancer cells. Lupeol modulates the microtubule assembly and the protein level of its regulatory molecules such as Stathmin and Survivin in prostate cancer cells thus causing G2/M cell cycle arrest^[1]. Lupeol has been shown to act as a potent inhibitor of protein kinases and serine proteases and inhibit the activity of DNA topoisomerase II, a target for anticancer chemotherapy^[2].
Cell Research	Cell lines	LNCaP cells
	Concentrations	20 μM
	Incubation Time	48 h
	Method	Microarray analysis: LNCaP cells were treated with subtoxic dose (20 μM) of Lupeol. After 48 h of incubation, cells were harvested and RNA was isolated by using RNeasy kit. Next, 4 μg of RNA was enzymatically converted into complementary RNA, labeled and hybridized with the microarrays followed by detection with the chemiluminescent reagents and X-ray film.

In Vivo
In vivo	Topical application of Lupeol decreases myeloperoxidase levels thus causing reduction in cell infiltration into inflamed tissues in mice. Oral administration of Lupeol (12.5-200 mg/kg) results in the significant reduction in CD4+ T and CD8+ T cell counts and the level of cytokines (IL-2, IFN-gamma and IL-4) in arthritic mice. Lupeol administration causes a significant reduction in cellularity and eosinophil levels in the broncho-alveolar fluid. It also exerts its wound healing effect by decreasing the level of monocytes and docking with GSK3β protein. For cancer, Lupeol significantly inhibits the NFκB translocation and its DNA binding activity in a mouse model of skin tumorigenesis. It inhibits growth of highly metastatic tumors of human melanoma origin by modulating ratio of Bcl-2 and Bax protein levels in vitro and in vivo. Thus, Lupeol itself being non-toxic to normal cells could be used as a chemopreventive as well chemotherapeutic agent against skin cancer. Lupeol has been shown to inhibit the generation of ROS and restore the depleted antioxidant levels within prostatic tissue of androgen pretreated mice. Lupeol is a non-toxic but highly potent chemopreventive and chemotherapeutic agent^[1].
Animal Research	Animal Models	CD-1 mice
	Dosages	1 or 2 mg/0.2 ml acetone/animal, w/v
	Administration	topical

References

Chemical Information & Solubility

Molecular Weight	426.72	Formula	C₃₀H₅₀O
CAS No.	545-47-1	SDF	Download Lupeol SDF
Smiles	CC(=C)C1CCC2(C1C3CCC4C5(CCC(C(C5CCC4(C3(CC2)C)C)(C)C)O)C)C
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 3 mg/mL ( (7.03 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):